For adults with leukemia, five years of disease-free survival technically constitutes a cure. But how should doctor and patient view reaching this milestone? Cautiously, writes oncologist Mikkael Sekeres, MD, MS, Director of Cleveland Clinic’s Leukemia Program, in his New York Times column.
Cleveland Clinic/North American Cooperative Group phase II study shows improved overall response rate with combination therapy in certain patient subgroups with myelodysplastic syndromes and myelomonocytic leukemia.
Doctors bring expertise to NCI-designated cancer center.
Healthcare providers and patients have disparate views of the course of MDS and the value and limitations of treatment. Improved communication and education may increase understanding of the diseases and improve outcomes.